Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
241-260 of 936 trials

Multiple Myeloma: Testing ISB 2001

We are investigating a new drug called ISB 2001 for patients with relapsed or refractory multiple myeloma. This trial aims to see how well it works in treating this challenging condition.

Relapsed/Refractory Multiple Myeloma1-2 yearsSafety phase (I)HematologyOncology

Leucettinib-21: Safety and Effects Study

We are investigating the safety and effects of Leucettinib-21 in healthy individuals and patients with Down Syndrome and Alzheimer’s. This study aims to understand how the drug works in different populations.

Healthy ParticipantsSafety phase (I)Neurology

Advanced Solid Tumors: INCB161734 Treatment

We are testing a new drug for patients with advanced or metastatic solid tumors that have the KRAS G12D mutation. The study aims to understand the safety and dosage of this treatment.

Advanced Cancer>2 yearsSafety phase (I)Oncology

Prostate Cancer: uPAR PET Imaging Study

We are investigating a new imaging method to help classify prostate cancer grades in men with localized, untreated disease. This study aims to assess the safety and effectiveness of this non-invasive technique.

Prostate Cancer≤3 monthsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncologyOtolaryngology

Breast Cancer: Vepdegestrant and Samuraciclib Study

We are investigating the safety and effectiveness of a new oral medication combined with another treatment for adults with advanced or metastatic hormone receptor-positive breast cancer. This study aims to find better treatment options for patients facing this condition.

Advanced Breast CancerSafety phase (I)Efficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Non-Small Cell Lung Cancer: Divarasib with Other Therapies

We are studying the safety and effectiveness of divarasib combined with pembrolizumab and chemotherapy in patients with untreated advanced lung cancer that has a KRAS G12C mutation. This research aims to find the best dose and treatment approach.

Non-Small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Zilovertamab Vedotin for Pediatric Cancers

We are studying a new treatment for children and young adults with blood cancers and solid tumors. The trial aims to assess its safety and how well it may work in these young patients.

Blood Cancers and Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPediatrics

MECP2 Duplication Syndrome: ION440 Treatment Study

We are testing a new treatment called ION440 to see if it is safe and well-tolerated in patients with MECP2 Duplication Syndrome. This study will also look at how the drug moves through the body.

MECP2 Duplication SyndromeSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHematology

Investigational Drug MP-101 for ALS and Alzheimer's Disease

We are studying how MP-101 affects laboratory signs of ALS and Alzheimer's in patients. This research aims to gather insights on its potential impact on these diseases.

Amyotrophic Lateral Sclerosis (ALS)Alzheimer’s Disease (AD)Safety phase (I)Neurology

Upper Limb Spasticity: New Botulinum Toxin Treatment

We are investigating a new injection for adults with upper limb spasticity to see if it is safe and effective compared to existing treatments. This study will help us understand how well it works over time.

Upper Limb Spasticity1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementNeurologyOrthopedics and Traumatology

B-Cell Aggressive Lymphoma: ARI0003 Cell Infusion

We are testing a new cell infusion treatment for patients with relapsed or refractory aggressive B-cell lymphoma. This study aims to see how well ARI0003 cells work in helping these patients.

Aggressive B-cell LymphomaSafety phase (I)Oncology

Hemophilia B: REGV131-LNP1265 Gene Therapy

We are studying a new gene therapy to see if it is safe and helps adults with Hemophilia B produce a vital clotting factor. The trial will also assess how it affects bleeding events.

Hemophilia B>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesHematologyInternal Medicine

Advanced Solid Tumors: AZD8421 Study

We are testing a new drug, AZD8421, to see how safe it is and how well it works for people with advanced or metastatic solid tumors. This study will help us understand its effects alone and in combination with other cancer treatments.

ER+ HER2- Advanced Breast CancerHigh-Grade Serous Ovarian Cancer (HGSOC)Safety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Dupuytren's Contracture: Bacterial Collagenase Treatment

We are studying a new bacterial collagenase injection for patients with Dupuytren's contracture to see if it improves hand function and reduces contracture compared to a placebo.

Dupuytren's Contracture6-12 monthsSafety phase (I)Efficacy phase (II)11-15 visitsInvestigational MedicinesOrthopedics and TraumatologyRheumatology

Prosetin for Amyotrophic Lateral Sclerosis (ALS)

We are evaluating a new drug called Prosetin to see how safe it is and how well it is tolerated in people with ALS and healthy volunteers. This study aims to understand its effects on ALS symptoms.

Amyotrophic Lateral SclerosisSafety phase (I)Post-Trial Drug AccessNeurology

B-Cell Malignancies: PIT565 Treatment Study

We are testing a new treatment called PIT565 for patients with relapsed or refractory B-cell malignancies. The goal is to see if it can improve outcomes for these patients.

Relapsed and Refractory B-cell Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukaemia>2 yearsSafety phase (I)Oncology

Advanced Prostate Cancer: 225Ac-PSMA-Trillium Study

We are testing a new treatment for men with advanced metastatic castration-resistant prostate cancer. This study aims to see how well it works and its safety in humans.

Castration-Resistant Prostate Cancer>2 yearsSafety phase (I)Oncology

Advanced Solid Tumors: MDNA11 and Pembrolizumab Study

We are investigating the safety and effectiveness of MDNA11, given alone or with pembrolizumab, in patients with advanced solid tumors. This study aims to find the best dose and understand how the treatment works.

Solid TumorSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Ulcerative Colitis: GRT-001 Treatment Study

We are evaluating a new treatment for ulcerative colitis in healthy volunteers and patients. The study aims to understand its safety and how it works in the body.

Ulcerative Colitis>2 yearsSafety phase (I)GastroenterologyInternal Medicine

Advanced Breast and Gastric Cancers: Disitamab Vedotin with Tucatinib

We are studying a new combination of disitamab vedotin and tucatinib for patients with advanced breast and gastric cancers. The goal is to find the best dose and evaluate its safety and effectiveness.

HER2 Positive Breast CancerOesophageal AdenocarcinomaGastric Cancer1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology